PazyarN, YaghoobiR, KazerouniA, FeilyA. Oatmeal in dermatology: A brief review. Indian J Dermatol Venereol Leprol, 2012; 78:142–145.
2.
GisondiP, MalaraG, ArdigòM. The psoriatic patient profile for infliximab. Eur Rev Med Pharmacol Sci, 2011; 15:1445–1451.
3.
PazyarN, YaghoobiR. Ginkgo biloba extract: A novel addition to antipsoriasis ammunition?J Altern Complement Med, 2012; 18:316–317.
4.
NamaziMR. Nicotinamide: A potential addition to the anti-psoriatic weaponry. FASEB J, 2003; 17:1377–1379.
5.
KruegerJG, BowcockA. Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis, 2005; 64,suppl 2:ii30–ii36.
6.
DerakhshanN. NFκB inhibitors as a potential novel hypothesized treatment for psoriasis. Sao Paulo Med J, 2011; 129:433–434.
7.
QaziBS, TangK, QaziA. Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis. Int J Inflam, 2011; 2011:908468.
8.
CrawshawAA, GriffithsCE, YoungHS. Investigational VEGF antagonists for psoriasis The University of Manchester, Manchester Academic Health Sciences Centre, Department of Dermatology, Manchester, UK. Expert Opin Investig Drugs, 2012; 21:33–43.
9.
SikarAktürk A, OzdoğanHK, BayramgürlerDet al.Nitric oxide and malondialdehyde levels in plasma and tissue of psoriasis patients. J Eur Acad Dermatol Venereol, 2011July13e-pub ahead of print.
10.
NamaziMR. Nicotinamide: A potential addition to the anti-psoriatic weaponry. FASEB J, 2003; 17:1377–1379.
11.
CampanatiA, OrcianiM, GorbiSet al.Effect of biologic therapies targeting TNF-alpha on cutaneous mesenchymal stem cells in psoriasis. Br J Dermatol, 2012Feb22e-pub ahead of print.
12.
DombrowskiY, PericM, KoglinSet al.Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med, 2011; 3:82ra38.
13.
SettinAA, HassanHA, El-BazRA, HassanTA. Association of cytokine gene polymorphisms with psoriasis in cases from the Nile delta of Egypt. Indian J Dermatol, 2011; 56:272–277.
14.
TekinNS, TekinIO, BarutF, SipahiEY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm, 2007; 2007:78454.
15.
HalickaD, ItaM, TanakaTet al.Biscoclaurine alkaloid cepharanthine protects DNA in TK6 lymphoblastoid cells from constitutive oxidative damage. Pharmacol Rep, 2008; 60:93–100.
16.
RogosnitzkyM, DanksR. Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions. Pharmacol Rep, 2011; 63:337–347.
17.
HarukiK, BrayPG, OnoM, WardSA. Potent enhancement of the sensitivity of Plasmodium falciparum to chloroquine by the bisbenzylisoquinoline alkaloid cepharanthine. Antimicrob Agents Chemother, 2000; 44:2706–2708.
18.
MurakamiK, OkajimaK, UchibaM. The prevention of lipopolysaccharide-induced pulmonary vascular injury by pretreatment with cepharanthine in rats. Am J Respir Crit Care Med, 2000; 161:57–63.
19.
HaradaK, FerdousT, ItashikiYet al.Cepharanthine inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing expression of vascular endothelial growth factor and interleukin-8. Int J Oncol, 2009; 35:1025–1035.
20.
SakaguchiS, FurusawaS, WuJ, NagataK. Preventive effects of a biscoclaurine alkaloid, cepharanthine, on endotoxin or tumor necrosis factor-alpha-induced septic shock symptoms: Involvement of from cell death in L929 cells and nitric oxide production in raw 264.7 cells. Int Immunopharmacol, 2007; 7:191–197.
